Hepatology · Rare DiseaseTrial Updateclinicalmid-term

Long-term Study on Odevixibat Effectiveness for PFIC in South Korea Initiated

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Ipsen3 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:31:03 AM

Assessment confidence: 88% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of a long-term study on odevixibat's effectiveness for PFIC in South Korea is significant as it may yield critical data that could influence the drug's market positioning against competitors. Monitoring this study's outcomes is essential for understanding the long-term viability of odevixibat in the rare disease space. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this study to assess the long-term viability of odevixibat in the PFIC market. The strongest clinical anchor is A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea (ClinicalTrials.gov), sub-indication match (rare disease); entity match (ipsen). In rare disease, 7 regulatory and 0 competitive items passed relevance filtering for Ipsen.

Competitive Pressure

The most relevant competitive pressure comes from This study may provide critical data on the long-term use of odevixibat, potentially influencing its market position against other therapies for PFIC..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). The study's findings may lead to new insights that could influence future regulatory decisions or labeling updates by the MFDS, affecting compliance and market access.

Key Risks

Elevated medium regulatory exposure for Ipsen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The results of this study could affect odevixibat's market share and competitive positioning in the PFIC treatment landscape, potentially impacting revenue streams for Ipsen.
Portfolio teams should monitor the outcomes of this study to assess the long-term viability of odevixibat in the PFIC market.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results from the study and any subsequent regulatory feedback from the MFDS.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
ClinicalTrials.govhigh relevance
Sub-indication match (rare disease); Entity match (ipsen)
FDA document
View source
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
ClinicalTrials.govmedium relevance
Sub-indication match (rare disease)
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
EVERO Drug-coated Balloon (DCB) Randomized Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Antecedent Metabolic Health and Metformin Aging Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Study Reveals GES Variants Impact Resistance to Ceftazidime-Avibactam and Imipenem-Relebactam
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effectiveness of tobacco cessation interventions delivered in clinical settings in South Asia: a systematic review and meta-analysis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ipsen

Commercial impact

medium

The results of this study could affect odevixibat's market share and competitive positioning in the PFIC treatment landscape, potentially impacting revenue streams for Ipsen.

Regulatory impact

medium

The study's findings may lead to new insights that could influence future regulatory decisions or labeling updates by the MFDS, affecting compliance and market access.

What to watch

Key milestones include interim results from the study and any subsequent regulatory feedback from the MFDS.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.